People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a lower likelihood of hospitalization, a study reports. These findings support referring PAH patients to specialty care centers for treatment, where factors like more careful disease monitoring might be decisive. The…
News
Paula Menezes has been awarded a $50,000 PHenomenal Impact Fund for Global PH Research grant to identify challenges faced by pulmonary hypertension (PH) patients and caregivers in parts of Latin America. Menezes’ project proposal is titled “Living with Pulmonary Hypertension in Latin America: A Patient’s…
When used alone or in combination with other therapies, Opsumit (macitentan) can lower the mortality risk in patients with pulmonary arterial hypertension (PAH), a study found. The study, “Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice:…
Pregnant women with pulmonary arterial hypertension (PAH) should seek specialist care before giving birth and for months afterward, due to the risk of severe maternal complications and high rates of premature births, according to a study in China. The study, “Pregnancy outcomes in patients with pulmonary…
A protein called interleukin-32 may serve as a biomarker for pulmonary arterial hypertension (PAH) in scleroderma patients, for whom PAH is a severe complication. The study reporting the findings, “Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension,” was published in the journal …
Liquidia Technologies, a company developing an inhaled form of treprostinil for pulmonary arterial hypertension (PAH), has established an agreement to acquire the rare disease company and marketer of generic treprostinil injections, RareGen, strengthening the company’s efforts in the PAH field. Under the agreement, the two companies will…
U.S. veterans with pulmonary hypertension (PH) due to left heart disease and chronic lung disease are more likely to be inappropriately prescribed phosphodiesterase-5 inhibitors (PDE5i) if they have received care both in and out of the Veterans Health Administration (VA), a study has found. Other factors for…
Uptravi (selexipag), an approved oral therapy for adults with pulmonary arterial hypertension (PAH), appears to also be safe and effective as an add-on treatment for children and adolescents, improving several relevant markers of the disease, a small study found. Its researchers recommended larger…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…
The Pulmonary Hypertension Association (PHA) is inviting the patient community to participate in its virtual fashion show, set for Aug. 1, as part of its “PHA Connects: Summer PHling.” The fashion show, which has been featured for years at the PHA’s International PH Conference and…
Janssen Korea and Johnson & Johnson Innovation have launched an initiative to help advance breakthrough innovations to improve patient care during the COVID-19 pandemic, including those that can potentially diagnose pulmonary hypertension rapidly and early. The initiative, named “Seoul Innovation QuickFire Challenge for Healthcare in the…
Tyvaso (inhaled treprostinil) significantly improved the exercise capacity of people with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD), achieving its primary endpoint in the…
